RESUMEN
HMG-CoA reductase inhibitors (statins), lipoprotein lipase activators (PPARα agonists) or fibrates are commonly used for controlling increased lipid levels in hyperlipidemia. Fenofibrate (FEN) belongs to the second generation prodrug fibric acid (isobutyric acid) derivative belonging to lipoprotein lipase activator class of drug. Results of clinical studies suggest that FEN can substantially reduce severe acute respiratory syndrome coronavirus 2. alpha and beta variant infection in human cell efficiently. This review article provides an in-depth examination of critical analytical methodologies used in the pharmaceutical analysis of FEN in pure forms, biological samples and pharmaceuticals. According to literature study reports several analytical techniques have been used for determination of FEN alone or in the combined dosage forms. Based on the literature, it was determined that high-performance liquid chromatography and UV/vis-spectrophotometry are the most widely used methods for FEN analysis. Sahoo et al. have developed the best HPLC method in bulk and pharmaceutical dosage form with the retention time of 19.268 min using phosphate buffer (pH 3.0): acetonitrile in the ratio of 30:70 (% v/v) as mobile phase. The information presented here may provide a solid foundation for future research on FEN in the field of drug analysis.
Asunto(s)
COVID-19 , Fenofibrato , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Humanos , Fenofibrato/análisis , Hipolipemiantes , SARS-CoV-2 , Cromatografía Líquida de Alta Presión/métodos , Preparaciones FarmacéuticasRESUMEN
Acerola (Malpighia emarginata) by-product (ABP) has various bioactive compounds with hypoglycaemic, antioxidant and anti-inflammatory activity. The ABP effects on the biochemical changes in the enterohepatic axis caused by a high-fat diet (HFD) remains unclear. This study assessed whether the ABP or fenofibrate administration for 28 days interferes in lipid, glucose, or inflammatory changes in the enterohepatic axis of rats fed HFD. ABP induced in the rats fed HFD a reduction in body weight, serum lipids, blood glucose, and liver fat accumulation; increased insulin tolerance, and faecal bile acid excretion; regulated organic acid synthesis, faecal and colonic microbial growth; reduced M1 macrophage and increased M2 macrophage infiltration in the colon and liver, respectively. The fenofibrate did not improve the lipid or glucose alterations in enterohepatic axis of rats fed HFD. ABP has functional/nutraceutical potential in treating HFD-induced metabolic disorders with beneficial effects on lipid and glucose metabolism, and reduction of inflammation.
Asunto(s)
Fenofibrato , Malpighiaceae , Ratas , Animales , Dieta Alta en Grasa/efectos adversos , Glucosa/metabolismo , Fenofibrato/análisis , Fenofibrato/metabolismo , Fenofibrato/farmacología , Frutas/química , Hígado/metabolismo , Malpighiaceae/química , Lípidos/análisis , Metabolismo de los LípidosRESUMEN
A wide variety of active pharmaceutical ingredients are released into the environment and pose a threat to aquatic organisms. Drug products using micro- and nanoparticle technology can lower these emissions into the environment by their increased bioavailability to the human patients. However, due to this enhanced efficacy, micro- and nanoscale drug delivery systems can potentially display an even higher toxicity, and thus also pose a risk to non-target organisms. Fenofibrate is a lipid-regulating agent and exhibits species-related hazards in fish. The ecotoxic effects of a fenofibrate formulation embedded into a hydroxypropyl methylcellulose microparticle matrix, as well as those of the excipients used in the formulation process, were evaluated. To compare the effects of fenofibrate without a formulation, fenofibrate was dispersed in diluted ISO water alone or dissolved in the solvent DMF and then added to diluted ISO water. The effects of these various treatments were assessed using the fish embryo toxicity test, acridine orange staining and gene expression analysis assessed by quantitative RT polymerase chain reaction. Exposure concentrations were assessed by chemical analysis. The effect threshold concentrations of fenofibrate microparticle precipitates were higher compared to the formulation. Fenofibrate dispersed in 20%-ISO-water displayed the lowest toxicity. For the fenofibrate formulation as well as for fenofibrate added as a DMF solution, greater ecotoxic effects were observed in the zebrafish embryos. The chemical analysis of the solutions revealed that more fenofibrate was present in the samples with the fenofibrate formulation as well as fenofibrate added as a DMF solution compared to fenofibrate dispersed in diluted ISO water. This could explain the higher ecotoxicity. The toxic effects on the zebrafish embryo thus suggested that the formulation as well as the solvent increased the bioavailability of fenofibrate.
Asunto(s)
Fenofibrato/toxicidad , Contaminantes Químicos del Agua/toxicidad , Pez Cebra/crecimiento & desarrollo , Animales , Cromatografía Líquida de Alta Presión , Composición de Medicamentos , Embrión no Mamífero/efectos de los fármacos , Embrión no Mamífero/metabolismo , Fenofibrato/análisis , Fenofibrato/química , Regulación de la Expresión Génica/efectos de los fármacos , Espectrometría de Masas , Tamaño de la Partícula , Pruebas de Toxicidad , Pez Cebra/metabolismoRESUMEN
Mapping the spatial distribution of a drug throughout the gastrointestinal tract (GIT) after oral ingestion can provide novel insights into the interaction between the drug, the oral drug delivery system, and the GIT. Matrix-assisted laser desorption/ionization-mass spectrometry imaging (MALDI-MSI) is a molecular imaging technique that can analyze molecules in the cryosections of tissues, determining their localization with a spatial resolution of 10-100 µm. The overall aim of this study was to use MALDI-MSI to visualize the distribution and spatial location of a model prodrug (fenofibrate) through the rat GIT. Furthermore, the distribution and spatial colocalization of taurocholate and phospholipids in the rat GIT in relation to fenofibrate were investigated. Rats were given a fenofibrate suspension of 10 mg/mL by oral gavage. Blood samples were drawn, and the rats were euthanized at three different time points. The GIT was collected and frozen, and MALDI-MSI was applied on cross sections of the stomach and intestine. Fenofibrate was detected by MALDI-MSI throughout the GIT, which also revealed that fenofibrate was hydrolyzed to the active drug fenofibric acid already in the stomach. Furthermore, the presence of lyso-phosphatidylcholine (lyso-PC) and taurocholate was confirmed in the lumen of the small intestine. MALDI-MSI was shown to be a useful qualitative tool for localizing parent prodrugs and active drugs, with a possibility for gaining insight into not only the location for activation but also the role of endogenous molecules in the process.
Asunto(s)
Fenofibrato/análogos & derivados , Tracto Gastrointestinal/metabolismo , Imagen Molecular/métodos , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Administración Oral , Animales , Fenofibrato/administración & dosificación , Fenofibrato/análisis , Fenofibrato/farmacocinética , Masculino , Modelos Animales , Profármacos , Ratas , Análisis Espacial , Suspensiones , Distribución TisularRESUMEN
Pharmaceuticals are a group of ubiquitous emerging pollutants, many of which have been shown to undergo efficient photolysis in the environment. Photochemically produced reactive intermediates (PPRIs) sensitized by the pharmaceuticals in sunlit natural waters may induce photodegradation of coexisting compounds. In this study, the roles of coexisting contaminants on the phototransformation of pharmaceuticals were unveiled with the fibrate drugs gemfibrozil (GMF), fenofibrate (FNF), and fenofibric acid (FNFA) as model compounds. GMF undergoes initial concentration dependent photodegradation due to the involvement of singlet oxygen (1O2) initiated self-sensitized photolysis, and undergoes pH dependent photodegradation due to dissociation and hydroxyl radical (OH) generation. The decarboxylated intermediates of GMF and coexisting FNFA significantly accelerated the photodegradation of GMF. The promotional effects of the decarboxylated intermediates are attributed to generation of PPRIs, e.g. 1O2, superoxide (O2-), that subsequently react with GMF. Besides, FNFA can also promote the photodegradation of GMF through the electron transfer reaction from ground state GMF to excited state FNFA, leading to the formation of decarboxylated intermediates. The formed intermediates can subsequently also facilitate GMF photodegradation. The results presented here provided valuable novel insights into the effects of coexisting contaminants on the photodegradation of pharmaceuticals in polluted waters.
Asunto(s)
Fenofibrato/análogos & derivados , Gemfibrozilo/análisis , Luz , Preparaciones Farmacéuticas/análisis , Fotólisis , Contaminantes Químicos del Agua/análisis , China , Fenofibrato/análisis , Fenofibrato/efectos de la radiación , Gemfibrozilo/efectos de la radiación , Concentración de Iones de Hidrógeno , Modelos Teóricos , Estructura Molecular , Preparaciones Farmacéuticas/efectos de la radiación , Ríos/química , Contaminantes Químicos del Agua/efectos de la radiaciónRESUMEN
Fibrates, which are widely used lipidaemic-modulating drugs, are emerging environmental pollutants. However, fibrate concentrations in the environment have not been thoroughly surveyed. Here, we determined concentrations of the most commonly used fibrates and their metabolites in source water and drinking water samples from ten drinking water treatment plants in Shanghai and Zhejiang, China, using solid-phase extraction and liquid chromatography-tandem mass spectrometry. All the target compounds were detected in at least some of the source water samples, at concentrations ranging from 0.04 ng/L (fenofibrate) to 1.53 ng/L (gemfibrozil). All the compounds except fenofibrate were also detected in at least some of the drinking water samples, at recoveries ranging from 35.5% to 91.7%, suggesting that these compounds are poorly removed by typical drinking water treatment processes. In a peroxisome proliferator-activated receptor α agonistic activity assay, the target compounds showed no significant activity at nanogram per litre concentrations; therefore, our results suggest that the fibrate concentrations in drinking water in Shanghai and Zhejiang, China do not significantly affect human health. However, because of the increasing westernization of the Chinese diet, fibrate use may increase, and thus monitoring fibrate concentrations in aquatic environments and drinking water in China will become increasingly important.
Asunto(s)
Agua Potable/análisis , Fenofibrato/análisis , Gemfibrozilo/análisis , Contaminantes Químicos del Agua/análisis , China , Cromatografía Liquida , Agua Potable/química , Monitoreo del Ambiente/métodos , Fenofibrato/aislamiento & purificación , Gemfibrozilo/aislamiento & purificación , Humanos , Extracción en Fase Sólida , Espectrometría de Masas en Tándem , Contaminantes Químicos del Agua/aislamiento & purificación , Purificación del Agua/métodosRESUMEN
BACKGROUND: Within the framework of routine fitness examinations, French Air Force military crew underwent urine testing for 3,4 methylenedioxymetamphetamine (MDMA [ecstasy]). The cross-reactivity of a dyslipidemic drug, fenofibrate, with an MDMA immunoassay was studied and confirmed on a large population sample. METHODS: A 3-year retrospective study was performed on the MDMA DRI Ecstasy Assay on the Unicel DXC 600. In the event of positive test result, a confirmatory testing was carried out by gas chromatography/mass spectrometry (GC/MS) to establish the presence of MDMA. When analysis by GC/MS did not confirm the presence of MDMA, a false-positive result was suspected and the samples were analyzed by high-performance liquid chromatography-mass spectrometry to identify a potential interfering substance. RESULTS: A total of 15,169 urine samples, from 7,803 patients, were tested for 3 years. Of the tested samples, 22 (0.15%) were positive by DRI Ecstasy Assay. None of them were positive by GC/MS. A cross-reactivity of fenofibrate's metabolite with MDMA using this assay was systematically found. CONCLUSION: Fenofibrate's interference with MDMA immunoassay was confirmed. Fenofibrate being widely prescribed, physicians had to be alerted that this treatment could lead to false-positive results.
Asunto(s)
Evaluación Preclínica de Medicamentos/normas , Reacciones Falso Positivas , Fenofibrato/análisis , N-Metil-3,4-metilenodioxianfetamina/orina , Adolescente , Adulto , Anciano , Evaluación Preclínica de Medicamentos/métodos , Fenofibrato/uso terapéutico , Fenofibrato/orina , Técnica del Anticuerpo Fluorescente Directa/métodos , Técnica del Anticuerpo Fluorescente Directa/normas , Francia , Cromatografía de Gases y Espectrometría de Masas/métodos , Humanos , Masculino , Persona de Mediana Edad , Personal Militar/estadística & datos numéricos , N-Metil-3,4-metilenodioxianfetamina/análisisRESUMEN
ABSTRACT Fibrates are drugs used for the treatment of hypertriglyceridemia and for the prevention of atherosclerosis. Three drugs in the fibrate class, ciprofibrate, fenofibrate and bezafibrate, were chosen for this study because their raw materials are readily available and because scientific publications on these compounds is limited. To evaluate their intrinsic stability, the drugs were exposed to a test condition (temperature, oxidation, UV light exposure, hydrolysis at different pH values and metal ions in solution) and then were subjected to analysis by HPLC. The samples were run on a C18 column, with a flow rate of 1.0 mL min-1 in a mobile phase consisting of methanol: 0.01 % phosphoric acid v/v (80:20), with variable detection wavelengths in the UV spectra. The analysis methodology showed satisfactory performance parameters. The three drugs were very unstable, degrading in each of the conditions evaluated. The test conditions of acid and basic hydrolysis showed the most significant degradation. The results demonstrated that the drugs in this class are unstable. Based on these experimentally determined degradation kinetics, it is easy to understand and emphasize the importance of the lack of liquid dosage forms on the market for fibrates because of their instability.
Asunto(s)
Fenofibrato/análisis , Bezafibrato/análisis , Cinética , Ácidos Fíbricos/análisis , Hipertrigliceridemia , Cromatografía Líquida de Alta Presión/métodos , Ácidos Fíbricos/clasificaciónRESUMEN
Purpose of this study was to investigate the ability of octenyl succinic anhydride (OSA) starch as emulsifier and solid carrier in dry emulsion (DE) and dry suspension (DS) formulations. Fenofibrate (FF) was loaded at lower and higher than its saturation concentration in oil phase to prepare the DE and DS by spray drying method. The DE and DS were successfully prepared with 36-48% and 46% production yield, respectively. After reconstitution in water, the emulsion with mean droplet size of 1-2 µm was obtained. Solid state characterization revealed the amorphous state of FF and the crystalline state of OSA starch in both DE and DS formulations. Both DE and DS enhanced FF dissolution rate compared to pure material and DS showed the highest dissolution rate. The DE and DS could be compressed to the tablets with acceptable disintegration time and without changeable dissolution profile. Moreover, the dissolution profiles of both DE and DS remained unchanged after 2 months storage at 40 °C.
Asunto(s)
Portadores de Fármacos/síntesis química , Emulsionantes/síntesis química , Fenofibrato/síntesis química , Almidón/síntesis química , Anhídridos Succínicos/síntesis química , Química Farmacéutica , Portadores de Fármacos/análisis , Emulsionantes/análisis , Fenofibrato/análisis , Solubilidad , Almidón/análisis , Anhídridos Succínicos/análisis , Suspensiones , Difracción de Rayos X/métodosRESUMEN
High performance liquid chromatography (HPLC) and second-order derivative spectrophotometry have been used for simultaneous determination of pravastatin (PS) and fenofibrate (FF) in pharmaceutical formulations. HPLC separation was performed on a phenyl HYPERSIL C18 column (125 mm × 4.6 mm i.d., 5 µm particle diameter) in the isocratic mode using a mobile phase acetonitrile/0.1 % diethyl amine (50:50, V/V, pH 4.5) pumped at a flow rate of 1.0 mL min-1. Measurement was made at 240 nm. Both drugs were well resolved on the stationary phase, with retention times of 2.15 and 5.79 min for PS and FF, respectively. Calibration curves were linear (R = 0.999 for PS and 0.996 for FF) in the concentration range of 5-50 and 20-200 µg mL-1 for PS and FF, respectively. Pravastatin and fenofibrate were quantitated in combined preparations also using the second-order derivative response at 237.6 and 295.1 nm for PS and FF, respectively. Calibration curves were linear, with the correlation coefficient R = 0.999 for pravastatin and fenofibrate, in the concentration range of 5-20 and 3-20 µg mL-1 for PS and FF, respectively. Both methods were fully validated and compared, the results confirmed that they were highly suitable for their intended purpose.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Fenofibrato/análisis , Pravastatina/análisis , Espectrofotometría Ultravioleta/métodos , Calibración , Combinación de Medicamentos , Fenofibrato/administración & dosificación , Pravastatina/administración & dosificaciónRESUMEN
Freeze drying is a complex, time consuming and thus expensive process, hence creating a need for understanding the material behaviour in the process environment and for process optimization. Near-infrared (NIR) spectroscopy offers the opportunity to monitor physicochemical changes of the formulation during freeze-drying. The aim of this work was to examine whether NIR spectroscopy allows in-line monitoring of all components during the entire freeze-drying process of a multi-component pharmaceutical formulation (a solution of fenofibrate and mannitol in a mixture of tertiary-butyl alcohol, and water). To extract useful information of all components in the formulation from the large multivariate data-sets obtained during in-line spectroscopic monitoring, several spectral pre-processing techniques and spectral data analysis techniques such as the mean of selected wavenumbers (Mws), the correlation coefficient (CorrCoef) and principal component analysis (PCA) have been evaluated and compared. To find out whether these chemometric techniques are also able to differentiate between changes in the process settings influencing the freeze-drying process of the formulation, freeze-drying processes were performed at four different conditions. Results demonstrated that in-line measurements using NIR spectroscopy were possible in an icy environment and that a further process understanding could be obtained. Data-analysis revealed the crystallization behaviour of each of the four components. In addition, using the three pre-processing techniques allowed observe the sublimation of the solvents. Mws and CorrCoef have proven to be adequate methods for monitoring the main physicochemical changes of product during the processes; this affirmation was confirmed by observing the outputs of PCA for entire processes.
Asunto(s)
Fenofibrato/análisis , Manitol/análisis , Espectroscopía Infrarroja Corta , Química Farmacéutica , Cristalización , Liofilización , Análisis de Componente Principal , Soluciones/química , Agua/química , Difracción de Rayos X , Alcohol terc-Butílico/químicaRESUMEN
Self-emulsifying drug delivery systems (SEDDS) are complex mixtures in which drug quantification can become a challenging task. Thus, a general need exists for novel analytical methods and a particular interest lies in techniques with the potential for process monitoring. This article compares Raman spectroscopy with high-resolution ultrasonic resonator technology (URT) for drug quantification in SEDDS. The model drugs fenofibrate, indomethacin, and probucol were quantitatively assayed in different self-emulsifying formulations. We measured ultrasound velocity and attenuation in the bulk formulation containing drug at different concentrations. The formulations were also studied by Raman spectroscopy. We used both, an in-line immersion probe for the bulk formulation and a multi-fiber sensor for measuring through hard-gelatin capsules that were filled with SEDDS. Each method was assessed by calculating the relative standard error of prediction (RSEP) as well as the limit of quantification (LOQ) and the mean recovery. Raman spectroscopy led to excellent calibration models for the bulk formulation as well as the capsules. The RSEP depended on the SEDDS type with values of 1.5-3.8%, while LOQ was between 0.04 and 0.35% (w/w) for drug quantification in the bulk. Similarly, the analysis of the capsules led to RSEP of 1.9-6.5% and LOQ of 0.01-0.41% (w/w). On the other hand, ultrasound attenuation resulted in RSEP of 2.3-4.4% and LOQ of 0.1-0.6% (w/w). Moreover, ultrasound velocity provided an interesting analytical response in cases where the drug strongly affected the density or compressibility of the SEDDS. We conclude that ultrasonic resonator technology and Raman spectroscopy constitute suitable methods for drug quantification in SEDDS, which is promising for their use as process analytical technologies.
Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Preparaciones Farmacéuticas/análisis , Sonido , Espectrometría Raman/métodos , Tecnología Farmacéutica/métodos , Calibración , Cápsulas , Cromatografía Líquida de Alta Presión/instrumentación , Cromatografía Líquida de Alta Presión/métodos , Emulsiones , Fenofibrato/administración & dosificación , Fenofibrato/análisis , Indometacina/administración & dosificación , Indometacina/análisis , Límite de Detección , Estructura Molecular , Preparaciones Farmacéuticas/administración & dosificación , Probucol/administración & dosificación , Probucol/análisis , Estándares de Referencia , Solubilidad , Espectrometría Raman/instrumentación , Tecnología Farmacéutica/instrumentaciónRESUMEN
The performance of four different lipid-based (Tween 80-Captex 200P, Tween 80-Capmul MCM, Tween 80-Caprol 3GO and Tween 80-soybean oil) and one commercially available micronized formulation (Lipanthyl Micronized(®)) of the lipophilic compound fenofibrate was compared in vitro in various biorelevant media and in vivo in rats. In simulated gastric fluid without pepsin (SGF(sp)) and fasted state simulated intestinal fluid (FaSSIF), only Tween 80-Captex 200P system resulted in a stable fenofibrate concentration, but no supersaturation was obtained. The other three lipid based systems created fenofibrate supersaturation; however they did not maintain it. In fed state simulated intestinal fluid (FeSSIF), all lipid-based formulations resulted in complete dissolution of fenofibrate during the experiment, which represented a supersaturated state for Tween 80-Capmul MCM and Tween 80-Caprol 3GO systems. In both FaSSIF and FeSSIF, all lipid-based formulations yielded a higher fenofibrate concentration than the micronized formulation. Contrary to the in vitro results, no significant difference in the in vivo performance was observed among the four tested lipid-based formulations both in the fasted and the fed states. The in vivo performance of all lipid-based formulations was better than that of Lipanthyl Micronized(®), in the fasted as well as in the fed state. The fact that for the lipid based systems the in vitro differences in pharmaceutical performance were not translated into in vivo differences can be attributed to the continuous excretion of bile in the gastrointestinal tract of rats, causing enhanced solubilizing capacity for lipophilic drugs. This study clearly points to the conflicting situation that might arise during the preclinical phase of the development of lipid based formulations of lipophilic drugs as the performance of such systems is very often evaluated by both in vitro release studies in human biorelevant media as well as in vivo studies in rats. Care must be taken to select a relevant animal model.
Asunto(s)
Caprilatos/química , Sistemas de Liberación de Medicamentos , Fenofibrato/química , Glicéridos/química , Hipolipemiantes/química , Polisorbatos/química , Tensoactivos/química , Animales , Composición de Medicamentos , Excipientes/química , Fenofibrato/análisis , Fenofibrato/sangre , Contenido Digestivo/efectos de los fármacos , Tracto Gastrointestinal/fisiología , Humanos , Hipolipemiantes/análisis , Hipolipemiantes/sangre , Masculino , Modelos Animales , Ratas , Ratas Wistar , Solubilidad , Aceite de SojaRESUMEN
The ability of in vitro biorelevant dissolution tests to predict the in vivo performance of nanosized fenofibrate (Lipidil 145 ONE®) and microsized fenofibrate (Lipidil - Ter®) was evaluated in this study. In vitro dissolution was carried out using USP apparatus 2 (paddle method) with updated biorelevant media to simulate the pre- and postprandial states. Membrane filters with different pore sizes were evaluated for their ability to hold back undissolved, nanosized drug particles. It was shown that filters with pore sizes of 0.1 µm and 0.02 µm were able to separate molecularly dissolved drug from colloidal and undissolved particles. In vitro results obtained with a suitable filter were used to generate simulated plasma profiles in combination with two different models using STELLA® software: (a) under the assumption of no permeability restrictions to absorption and (b) under the assumption of a permeability restriction. The simulated plasma profiles were compared to in vivo data for the nanosized and the microsized formulation in the fasted and fed states. The first model approach resulted in good correlation for the microsized fenofibrate formulation, but the plasma profile of the formulation containing nanosized fenofibrate was overpredicted in the fasted state. The second model successfully correlated with in vivo data for both formulations, regardless of prandial state. Comparison of simulations with the two models indicates that in the fasted state, absorption of fenofibrate from the nanosized formulation is at least partly permeability-limited, while for the microsized formulation the dissolution of fenofibrate appears to be rate-determining.
Asunto(s)
Fenofibrato/química , Fenofibrato/farmacocinética , Hipolipemiantes/química , Hipolipemiantes/farmacocinética , Absorción , Simulación por Computador , Ayuno , Fenofibrato/análisis , Fenofibrato/sangre , Filtración , Humanos , Hipolipemiantes/análisis , Hipolipemiantes/sangre , Nanopartículas , Tamaño de la Partícula , Permeabilidad , Periodo Posprandial , SolubilidadRESUMEN
With reference to common application of HPLC to routine analytical tests on medicinal products decreasing the level of cholesterol, including three compounds from this group--fenofibrate, bezafibrate and etofibrate, we developed a new method for determining two other compounds--ciprofibrate and gemfibrozil. The developed HPLC method may be used for identification and qualitative determination of selected compounds--derivatives of aryloxyalkylcarboxylic acids as well as it may be used for simultaneous separation and determination of all compounds from the group of fibrates using one column and the same methodology. The results and statistical data indicate good sensitivity and precision. The RSD value presented is equivalent to the newly developed method of determinination of ciprofibrate and gemfibrozil in the substances and medicinal products--capsules and coated tablets.
Asunto(s)
Anticolesterolemiantes/análisis , Cromatografía Líquida de Alta Presión/métodos , Bezafibrato/análisis , Ácido Clofíbrico/análogos & derivados , Ácido Clofíbrico/análisis , Fenofibrato/análisis , Ácidos Fíbricos , Gemfibrozilo/análisisRESUMEN
The amount and distribution of six pharmaceutical compounds belonging to distinct therapeutic classes were investigated along the navigation channel of the Douro River estuary. Distinct spatial and temporal trends were considered and a total of 87 water samples were pre-concentrated by solid-phase extraction (SPE) and analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS) with an ion trap (IT) analyzer and electrospray ionization (ESI). The maximum concentrations found were 178ng/L for carbamazepine, 3.65ng/L for diazepam, 70.3ng/L for fenofibric acid, 3.18ng/L for propranolol, 15.7ng/L for trimethoprim and 53.3ng/L for sulfamethoxazole. Carbamazepine was the most ubiquitous compound with 100% positive detection frequency followed by propranolol (38%), trimethoprim (34%) and sulfamethoxazole (33%). The pharmaceutical compounds were quantified at higher levels in the lower stretch of the estuary, especially near the wastewater treatment plant (WWTP). The data proves that pollution of the Douro River estuary by pharmaceuticals is consistent and is occurring in a fairly constant manner in time, covering a wide area and displaying hot-spots. Individually, the concentration levels are not likely to cause acute effects, based on reference experimental data. However, the fact that complex mixtures exist gives cause for concern as regards potentially relevant toxicological risks. The study points out the need for continuous monitoring of contamination levels not only in the Douro River estuary but also in other major estuaries. Finally, the scenario supports the need for experimental studies on toxicological impacts on aquatic organisms at environmentally relevant concentrations.
Asunto(s)
Monitoreo del Ambiente , Preparaciones Farmacéuticas/análisis , Ríos/química , Contaminantes Químicos del Agua/análisis , Carbamazepina/análisis , Carbamazepina/toxicidad , Cromatografía Liquida , Diazepam/análisis , Diazepam/toxicidad , Fenofibrato/análogos & derivados , Fenofibrato/análisis , Fenofibrato/toxicidad , Portugal , Propranolol/análisis , Propranolol/toxicidad , Medición de Riesgo , Extracción en Fase Sólida , Sulfametoxazol/análisis , Sulfametoxazol/toxicidad , Trimetoprim/análisis , Trimetoprim/toxicidad , Contaminantes Químicos del Agua/toxicidadRESUMEN
Etofibrate, fenofibrate, and atorvastatin were determined in their pharmaceutical preparations and human plasma using differential pulse polarographic and square wave voltammetric techniques by reduction at a dropping-mercury working electrode versus Ag/AgCl reference electrode. The reversibility of the electrode reactions was tested using cyclic voltammetry, and they were found to be irreversible reduction reactions. Optimum conditions such as pH, scan rate, and pulse amplitude were studied, and validation of the proposed methods was performed. The proposed methods proved to be accurate, precise, robust, and specific for determination of the 3 drugs. The relative standard deviation values were <2%, indicating that these methods are precise. Limits of detection and quantitation were in the ranges of 0.037-0.21 and 0.12-0.71 microg/mL, respectively, indicating high sensitivity.
Asunto(s)
Anticolesterolemiantes/análisis , Ácido Clofíbrico/análogos & derivados , Fenofibrato/análisis , Ácidos Heptanoicos/análisis , Hipolipemiantes/análisis , Pirroles/análisis , Anticolesterolemiantes/sangre , Atorvastatina , Ácido Clofíbrico/análisis , Ácido Clofíbrico/sangre , Electroquímica , Fenofibrato/sangre , Ácidos Heptanoicos/sangre , Humanos , Concentración de Iones de Hidrógeno , Hipolipemiantes/sangre , Indicadores y Reactivos , Polarografía , Pirroles/sangre , Estándares de Referencia , Reproducibilidad de los Resultados , SolucionesRESUMEN
A stability indicating UPLC method was developed and validated for the simultaneous determination of atorvastatin, fenofibrate and their impurities in tablets. The chromatographic separation was performed on acquity UPLC BEH C18 column (1.7 microm, 2.1 mmx100 mm) using gradient elution of acetonitrile and ammonium acetate buffer (pH 4.7; 0.01 M) at flow rate of 0.5 ml/min. UV detection was performed at 247 nm. Total run time was 3 min within which main compounds and six other known and major unknown impurities were separated. Stability indicating capability was established by forced degradation experiments and separation of known degradation products. The method was validated for accuracy, repeatability, reproducibility and robustness. Linearity, LOD and LOQ was established for atorvastatin, fenofibrate and their known impurities.
Asunto(s)
Anticolesterolemiantes/análisis , Cromatografía Líquida de Alta Presión/métodos , Contaminación de Medicamentos/prevención & control , Fenofibrato/análisis , Ácidos Heptanoicos/análisis , Pirroles/análisis , Anticolesterolemiantes/química , Anticolesterolemiantes/metabolismo , Atorvastatina , Tampones (Química) , Estabilidad de Medicamentos , Fenofibrato/química , Fenofibrato/metabolismo , Ácidos Heptanoicos/química , Ácidos Heptanoicos/metabolismo , Concentración de Iones de Hidrógeno , Estructura Molecular , Pirroles/química , Pirroles/metabolismo , Estándares de Referencia , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Comprimidos , Factores de TiempoRESUMEN
Two simple and accurate methods to determine atorvastatin calcium (ATO) and fenofibrate (FEN) in combined dosage forms were developed using second-derivative spectrophotometry and reversed-phase liquid chromatography (LC). ATO and FEN in combined preparations (tablets) were quantitated using the second-derivative responses at 245.64 nm for ATO and 289.56 nm for FEN in spectra of their solution in methanol. The calibration curves were linear [correlation coefficient (r) = 0.9992 for ATO and 0.9995 for FEN] in the concentration range of 3-15 microg/mL for ATO and FEN. In the LC method, analysis was performed on a Hypersil ODS-C18 column (250 mm x 4.6 mm id, 5 microm particle size) in the isocratic mode using the mobile phase methanol-water (90 + 10, v/v), adjusted to pH 5.5 with orthophosphoric acid, at a flow rate of 1 mL/min. Measurement was made at a wavelength of 246.72 nm. Both drugs were well resolved on the stationary phase, and the retention times were 1.95 min for ATO and 5.50 min for FEN. The calibration curves were linear (r = 0.9985 for ATO and 0.9976 for FEN) in the concentration range of 3-15 microg/mL for ATO and FEN. Both methods were validated, and the results were compared statistically. They were found to be accurate, precise, and specific. The methods were successfully applied to the estimation of ATO and FEN in combined tablet formulations.
Asunto(s)
Química Farmacéutica/métodos , Fenofibrato/análisis , Ácidos Heptanoicos/análisis , Pirroles/análisis , Anticolesterolemiantes/análisis , Atorvastatina , Calibración , Química Farmacéutica/instrumentación , Cromatografía Liquida/métodos , Formas de Dosificación , Fenofibrato/química , Ácidos Heptanoicos/química , Concentración de Iones de Hidrógeno , Hipolipemiantes/análisis , Modelos Químicos , Pirroles/química , Análisis de Regresión , Reproducibilidad de los Resultados , Espectrofotometría , Espectrofotometría Ultravioleta , ComprimidosRESUMEN
In the present work, five different spectrophotometric techniques for simultaneous determination of formulations containing atorvastatin calcium (ATOR) and fenofibrate (FENO) in various combinations are described. In ratio spectra derivative spectrophotometry, analytical signals were measured at wavelengths corresponding to either maximums or minimums for both drugs in first derivative spectra of ratio spectra obtained by using either spectrum as divisor. For the remaining four methods using chemometric techniques, namely, classical least squares (CLS), inverse least squares (ILS), principal component regression (PCR) and partial least squares (PLS), the calibrations were constructed by using the absorption data matrix corresponding to the concentration data matrix, with measurements in the range of 231 - 310 nm (Deltalambda = 1 nm) in their zero-order spectra. The linearity range was found to be 4 - 22 and 2 - 20 microg/ml for ATOR and FENO, respectively. The validity of the proposed methods was successfully assessed for analyses of both drugs in laboratory-prepared mixtures and in commercial tablet formulations.